Generation Bio Co (GBIO) concluded trading on Wednesday at a closing price of $0.56, with 9.47 million shares of worth about $5.3 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -38.59% during that period and on July 16, 2025 the price saw a gain of about 32.63%. Currently the company’s common shares owned by public are about 67.01M shares, out of which, 45.82M shares are available for trading.
Stock saw a price change of 49.31% in past 5 days and over the past one month there was a price change of 53.08%. Year-to-date (YTD), GBIO shares are showing a performance of -79.30% which decreased to -46.70% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.30 but also hit the highest price of $3.65 during that period. The average intraday trading volume for Generation Bio Co shares is 757.40K. The stock is currently trading 51.78% above its 20-day simple moving average (SMA20), while that difference is up 48.31% for SMA50 and it goes to -41.02% lower than SMA200.
Generation Bio Co (NASDAQ: GBIO) currently have 67.01M outstanding shares and institutions hold larger chunk of about 54.39% of that.
The stock has a current market capitalization of $37.87M and its 3Y-monthly beta is at 2.63. It has posted earnings per share of -$1.08 in the same period. It has Quick Ratio of 8.43 while making debt-to-equity ratio of 1.19. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for GBIO, volatility over the week remained 14.49% while standing at 10.18% over the month.
Stock’s fiscal year EPS is expected to rise by 45.62% while it is estimated to increase by 0.77% in next year. EPS is likely to grow at an annualized rate of 24.37% for next 5-years, compared to annual growth of -8.30% made by the stock over the past 5-years.
Coverage by Canaccord Genuity stated Generation Bio Co (GBIO) stock as a Buy in their note to investors on November 08, 2022, suggesting a price target of $9 for the stock. On December 14, 2021, William Blair Downgrade their recommendations, while on June 08, 2021, JMP Securities Initiated their ratings for the stock with a price target of $40. Stock get an Outperform rating from William Blair on February 24, 2021.
